Cardiometabolic Morbidity of Mild Cortisol Excess
Authors: André Lacroix
Journal: Annals of Internal Medicine (2022)

EditorialsMarch 2022Cardiometabolic Morbidity of Mild Cortisol ExcessAndré Lacroix, MDAndré Lacroix, MDEndocrine Division, Department of Medicine and Research Center, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-4526 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Incidental adrenal lesions are found during abdominal imaging in 2% to 7% of adults, and determining their cause and potential for malignancy, as well as their levels of excess hormone secretion, presents a challenge for clinicians (1–3). Most frequently, these lesions are benign adrenocortical adenomas without apparent excess steroid production. However, adenomas produce mild cortisol excess without clinical manifestations of Cushing syndrome (CS) in approximately 35% of cases, a condition formerly known as subclinical CS (1–3). Patients with overt adrenal CS are typically diagnosed during investigation of specific symptoms rather than by abdominal imaging for unrelated reasons.In unilateral adenomas ...References1. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1-G34. [PMID: 27390021] doi:10.1530/EJE-16-0467 CrossrefMedlineGoogle Scholar2. Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171:107-116. [PMID: 31234202] doi:10.7326/M18-3630 LinkGoogle Scholar3. Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab. 2021;106:3331-3353. [PMID: 34260734] doi:10.1210/clinem/dgab512 CrossrefMedlineGoogle Scholar4. Bonnet-Serrano F, Bertherat J. Genetics of tumors of the adrenal cortex. Endocr Relat Cancer. 2018;25:R131-R152. [PMID: 29233839] doi:10.1530/ERC-17-0361 CrossrefMedlineGoogle Scholar5. St-Jean M, Ghorayeb NE, Bourdeau I, et al. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract Res Clin Endocrinol Metab. 2018;32:165-187. [PMID: 29678284] doi:10.1016/j.beem.2018.01.003 CrossrefMedlineGoogle Scholar6. Chasseloup F, Bourdeau I, Tabarin A, et al. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol. 2021;9:813-824. [PMID: 34655521] doi:10.1016/S2213-8587(21)00236-9 CrossrefMedlineGoogle Scholar7. Pivonello R, Isidori AM, De Martino, et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611-29. [PMID: 27177728] doi:10.1016/S2213-8587(16)00086-3 CrossrefMedlineGoogle Scholar8. Prete A, Subramanian A, Bancos I, et al. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors. A cross-sectional multicenter study. Ann Intern Med. 2022;175:325-34. doi:10.7326/M21-1737 Google Scholar9. Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann Intern Med. 2021;174:1041-1049. [PMID: 34029490] doi:10.7326/M20-7946 LinkGoogle Scholar10. Sævik ÅB, Wolff AB, Björnsdottir S, et al. Potential transcriptional biomarkers to guide glucocorticoid replacement in autoimmune Addison's disease. J Endocr Soc. 2021;5:bvaa202. [PMID: 33553982] doi:10.1210/jendso/bvaa202 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Endocrine Division, Department of Medicine and Research Center, Centre hospitalier de l’Université de Montréal, Montréal, Québec, CanadaDisclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-4526.Corresponding Author: André Lacroix, MD, Endocrine Division, Department of Medicine and Research Center, Centre hospitalier de l’Université de Montréal, 1000 rue Saint-Denis, Montréal, QC, Canada, H2X 0A9; e-mail, andre.[email protected]ca.This article was published at Annals.org on 4 January 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors Alessandro Prete , Anuradhaa Subramanian , Irina Bancos , Vasileios Chortis , Stylianos Tsagarakis , Katharina Lang , Magdalena Macech , Danae A. Delivanis , Ivana D. Pupovac , Giuseppe Reimondo , Ljiljana V. Marina , Timo Deutschbein , Maria Balomenaki , Michael W. O’Reilly , Lorna C. Gilligan , Carl Jenkinson , Tomasz Bednarczuk , Catherine D. Zhang , Tina Dusek , Aristidis Diamantopoulos , Miriam Asia , Agnieszka Kondracka , Dingfeng Li , Jimmy R. Masjkur , Marcus Quinkler , Grethe Å. Ueland , M. Conall Dennedy , Felix Beuschlein , Antoine Tabarin , Martin Fassnacht , Miomira Ivović , Massimo Terzolo , Darko Kastelan , William F. Young Jr. , Konstantinos N. Manolopoulos , Urszula Ambroziak , Dimitra A. Vassiliadi , Angela E. Taylor , Alice J. Sitch , Krishnarajah Nirantharakumar , Wiebke Arlt , and Metrics March 2022Volume 175, Issue 3Page: 450-451KeywordsAdenomasAdrenal tumorsAdrenocorticotropic hormoneCortisol ePublished: 4 January 2022 Issue Published: March 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...